Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.

Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. J Natl Cancer Inst (2015) 1.77

Association between Aspirin Therapy and Clinical Outcomes in Patients with Non-Obstructive Coronary Artery Disease: A Cohort Study. PLoS One (2015) 0.80

How to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion. Postepy Kardiol Interwencyjnej (2015) 0.76

Cons outweigh pros of preventive aspirin in women, study finds. BMJ (2014) 0.75

Primary Prevention of Atherosclerotic Cardiovascular Disease in Women. Curr Cardiovasc Risk Rep (2015) 0.75

Aspirin use and mortality in two contemporary U.S. cohorts. Epidemiology (2017) 0.75

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32

Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J (2012) 13.74

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (2010) 13.13

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet (2012) 5.81

Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA (2007) 5.60

Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26

Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med (2012) 5.12

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol (2012) 3.37

Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology (2009) 3.20

The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94

Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med (2013) 2.33

Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2009) 1.89

Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med (1998) 1.71

Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials (2007) 1.58

Concordance for prognostic models with competing risks. Biostatistics (2014) 1.38

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J (2011) 1.35

Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ (2011) 1.32

Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines. Circ Cardiovasc Qual Outcomes (2011) 1.11

Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes (2014) 1.07

Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One (2013) 1.01

Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. Eur Heart J (2011) 1.00

Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. Eur Heart J (2014) 0.88

Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet (2016) 1.02

Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol Psychiatry (2014) 1.01

The relation between resting heart rate and cancer incidence, cancer mortality and all-cause mortality in patients with manifest vascular disease. Cancer Epidemiol (2014) 0.76

The daily 10 kcal expenditure deficit: a before-and-after study on low-cost interventions in the work environment. BMJ Open (2013) 0.75

Effect modification in the relation between HbA1c and cardiovascular disease and mortality in patients with type 2 diabetes. Diabetes Obes Metab (2016) 0.75